Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

GLP-1 RA use with subsequent prepregnancy or early pregnancy discontinuation linked to higher risk for preterm delivery, gestational diabetes.

For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...

Dual therapy with metformin and GLP-1 RAs is associated with a lower risk for adiposity-related cancers and mortality than DPP-4 inhibitor therapy in patients with T2D.

Weight loss drugs known as GLP-1 receptor agonists are sometimes referred to as “miracle drugs,” not only because they help people lose weight, but because they’ve also been shown to help with many ...

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

GLP-1 RAs are safe and efficacious for adults with IBD, with no increased risk for flare-ups, hospitalization, corticosteroid use, or operation.

Hispanic, Black non-Hispanic, White non-Hispanic adults more likely to use GLP-1 RA injectables than Asian non-Hispanics. (HealthDay News) — In 2024, 26.5 percent of adults with diagnosed diabetes ...

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the ...

According to a study published in Diabetes, Obesity and Metabolism, combining metformin with GLP-1 receptor agonists was ...